GlassScriptPhysician profile
Anthony Rivera Linares
NPI 1306840160
$1,570.47
in general payments reported to CMS, 2019-2025
15 companies · $79.85 in 2025
The $79.85 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $189 · 2021: $277 · 2022: $160 · 2023: $132 · 2024: $372 · 2025: $79.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $584.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $249.46 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $220.13 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $146.30 | 2020 | |
| Biocryst US Sales Co., LLC | $124.50 | 2024 | Orladeyo |
| Lilly USA, LLC | $113.31 | 2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $109.81 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $104.16 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $100.00 | 2021 | |
| Amgen INC. | $99.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.45 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $75.57 | 2019 | |
| Pbg Puerto Rico LLC | $70.00 | 2019-2021 | |
| Abbvie INC. | $25.25 | 2022 | |
| Pfizer Pharmaceuticals LLC | $20.00 | 2019 | |
| Mdd US Operations, LLC | $15.93 | 2023 | Gocovri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Rivera Linares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.